Infectious Disease Preclinical Deal Benchmarks — Ex-US (2026)
Median upfront of $29M with total deal values reaching $387M in Ex-US territory.
Median Upfront
$29M
Total Deal Value
$258M
Royalty Range
2.6%–6.1%
Territory Multiplier
0.45x
Understanding Infectious Disease Deal Benchmarks at Preclinical
Preclinical Infectious Disease licensing deals in Ex-US territory command a median upfront payment of $29M, with values ranging from $12M at the low end to $49M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $129M to $387M, with a median of $258M. Royalty rates for infectious disease assets at this stage typically fall between 2.6% and 6.1% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $12M | $29M | $49M |
| Total Deal Value | $129M | $258M | $387M |
| Royalty Rate | 2.6% | — | 6.1% |
Comparable Deals
No territory-specific comparable deals. Use the calculator for full analysis.
See All Comparable Deals
View 0 comparable Infectious Disease transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Preclinical Infectious Disease deals in Ex-US territory?
How does Ex-US territory affect Infectious Disease deal value?
What royalty rates are typical for Preclinical Infectious Disease licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$74M upfront
Infectious Disease · Phase 1 · Ex-US
$231M upfront
Infectious Disease · Phase 2 · Ex-US
$573M upfront
Infectious Disease · Phase 3 · Ex-US
$1.6B upfront
Infectious Disease · Approved · Ex-US
$15M upfront
Oncology · Preclinical · Ex-US
$15M upfront
Neurology/CNS · Preclinical · Ex-US
$32M upfront
Immunology · Preclinical · Ex-US
$35M upfront
Metabolic/Obesity · Preclinical · Ex-US
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Infectious Disease Preclinical Deal Benchmarks — Ex-US (2026). Retrieved from https://solidus.ambrosiaventures.co/data/infectious-disease-preclinical-deals-ex-us
<a href="https://solidus.ambrosiaventures.co/data/infectious-disease-preclinical-deals-ex-us">Infectious Disease Preclinical Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=infectiousDisease&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.